secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001193125-24-004882
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis raises 2023 R&D revenue guidance to $25-27M, updates cash and margin outlook
--------------------------------------------------------------------------------

- Unaudited pro forma cash ~$70M as of Dec 31, 2023; includes $5M upfront from Nestlé for CDX-7108 assignment.
- 2023 product revenue expected at upper end of $30M-$35M range (excl. PAXLOVID enzyme sales).
- R&D revenue guidance raised to $25M-$27M from $21M-$24M, reflecting $5M Q1 payment from Nestlé.
- Gross margin on product revenue guidance raised to 60%-65% from 55%-65% (excl. PAXLOVID).
- Cash expected to fund operations to positive cash flow around end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000119312524004882/0001193125-24-004882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000119312524004882/d710983d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-004882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer